retatrutide fat loss study FDA Approval Status 2026: Everything We Know So Far 28.7% Weight Loss in New

We were one of the first practices to launch a dedicated microdosing program because not every patient taking a GLP-1 is trying to lose weight

Concern about hypoglycemia risk

Do not have personal or family histories of certain medical conditions or allergies

Retatrutide is an investigational medication not approved by the FDA as of April 2026

This area lacks large clinical trials specific to retatrutide combinations, but the theoretical rationale is sound: using one compound for fat loss and another for muscle preservation addresses both sides of the body composition equation simultaneously

This approach is consistent with other agents in this class, such as semaglutide and tirzepatide